A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies

Trial Profile

A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Vorinostat
  • Indications Head and neck cancer; Salivary gland cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 06 Sep 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
    • 15 Mar 2016 Planned number of patients changed from 35 to 50 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top